1. Search Result
Search Result
Results for "

ALR2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Fluorescent Dye

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121933

    Aldose Reductase Metabolic Disease
    IDD388 is a selective aldose reductase (ALR2) inhibitor with an IC50 of 30 nM. IDD388 displays selectivity for ALR2 over ALR1 (IC50 of 14 μM) .
    IDD388
  • HY-150630

    Aldose Reductase Metabolic Disease
    ALR2-IN-1 is a potent and selective ALR2 inhibitor (IC50=1.42 μM). ALR2-IN-1 shows antioxidant and antiglycative properties. ALR2-IN-1 can be used in diabetic complication research .
    ALR2-IN-1
  • HY-175331

    Aldose Reductase Metabolic Disease Cancer
    ALR2-IN-7 (Compound 5a) is a highly potent and selective aldose reductase (ALR2/AKR1B1) inhibitor (Ki=8.71 nM). ALR2-IN-7 is promising for research of diabetic complications (e.g., retinopathy, nephropathy) and cancers .
    ALR2-IN-7
  • HY-D0064

    Aldose Reductase Metabolic Disease
    6,7-Dihydroxy-4-coumarinylacetic acid is a potent and selective inhibitor of ALR2. 6,7-Dihydroxy-4-coumarinylacetic acid inhibits ALR2, SDH andALR1 with IC50s of 9.6, 288 and 66.3 μM, respectively. 6,7-Dihydroxy-4-coumarinylacetic acid clearly suppresses galactitol accumulation .
    6,7-Dihydroxy-4-coumarinylacetic acid
  • HY-175854

    Aldose Reductase Cancer
    Aldose reductase-IN-9 (Compound 8b) is an Aldose reductase (ALR2) inhibitor with a Ki value of 3.59 nM. Aldose reductase-IN-9 has anti-tumor activity .
    Aldose reductase-IN-9
  • HY-151947

    Aldose Reductase Metabolic Disease
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications .
    ALR2-IN-3
  • HY-151946

    Aldose Reductase Metabolic Disease
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications .
    ALR2-IN-2
  • HY-176164

    Aldose Reductase Neurological Disease Metabolic Disease
    ALR2-IN-6 (compound 9) is a potent and competitive ALR2 inhibitor with a Ki of 0.064 μM. ALR2-IN-6 can be used in the study of neuropathy, retinopathy, and nephropathy .
    ALR2-IN-6
  • HY-162758

    Aldose Reductase Metabolic Disease
    ALR2-IN-5 (Compound 10a) is an inhibitor of ALR2 with an IC50 value of 99.29 nM. ALR2-IN-5 exhibits hypoglycemic effects and can be utilized in research related to diabetes .
    ALR2-IN-5
  • HY-175639

    Aldose Reductase Metabolic Disease Inflammation/Immunology
    ALR2-IN-8 is a potent aldose reductase (ALR2/AKR1B1) inhibitor with a KI of 7.34 nM. ALR2-IN-8 has extremely low toxicity to normal cells and has a weak direct killing effect on cancer cells. ALR2-IN-8 can used for the studies of diabetic and inflammation-linked disorders .
    ALR2-IN-8
  • HY-175862

    Aldose Reductase Reactive Oxygen Species (ROS) PI3K Akt SOD p38 MAPK Keap1-Nrf2 Metabolic Disease
    ALR2-IN-9 is a potent ALR2 inhibitor (IC50 = 21.8 nM) with excellent antioxidant activity (EC50 for DPPH radical scavenging = 2.8 μM). ALR2-IN-9 interacts directly with Reactive Oxygen Species (ROS)/Reactive Nitrogen Species (RNS) and interrupts the free radical chain reactions, and as an endogenous enzymatic antioxidant regulator, which regulates enzyme functions of CAT and SOD. ALR2-IN-9 regulates PI3K/Akt/Nrf2 pathway to attenuate hyperglycemia-mediated mitochondrial superoxide overproduction in vitro, and ameliorates CuSO4- and H2O2-induced oxidative stress in vivo. ALR2-IN-9 prolongs lifespan of C. elegans via the regulation of stress response genes such as PMK-1. ALR2-IN-9 is a promising anti-aging drug candidate. ALR2-IN-9 can be used for diabetic complication research .
    ALR2-IN-9
  • HY-147977

    Aldose Reductase Cancer
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity .
    ALR1/2-IN-1
  • HY-146129

    Aldose Reductase Metabolic Disease
    As an aldose reductase (ALR2) inhibitor, the compound is used to enhance the combination of inhibitory excitability and antioxidant capacity to delay the progress of diabetes complications.
    Aldose reductase-IN-5
  • HY-146661

    Aldose Reductase Cancer
    Aldose reductase-IN-4 (compund IIc) is an aldose reductase inhibitor with IC50s of 11.70 μM and 0.98 μM for aldehyde reductase 1 (ALR1) and ALR2, respectively .
    Aldose reductase-IN-4
  • HY-106697
    Ponalrestat
    1 Publications Verification

    ICI 128436

    Aldose Reductase Metabolic Disease
    Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol .
    Ponalrestat
  • HY-W011786

    Aldose Reductase Metabolic Disease
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole is an inhibitor of larval settlement in marine organisms, demonstrating low toxicity while effectively inhibiting the metamorphosis of species such as barnacles, bryozoans, and polychaetes. 2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole also exhibits activity as an aldose reductase (ALR2) inhibitor, indicating potential therapeutic applications in diabetes-related complications.
    2-Chloro-1-(4-fluorobenzyl)-1H-benzo[d]imidazole

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: